Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference
① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.
Clinical results did not meet expectations. Tasly Pharmaceutical Group suspends the eight-year development "marathon" of the new anti-cancer drug | Summary of the announcement.
① Tasly Pharmaceutical Group announced the suspension of the research and development of its anmeimu monoclonal antibody. Since its approval in 2016, the drug has reached the IIb phase of clinical research; ② According to the clinical research results, the efficacy of anmeimu monoclonal antibody did not meet expectations, and other EGFR monoclonal antibody biosimilar drugs face fierce competition; ③ This project also involves Sino Biopharmaceutical's equity participation, with Tasly Pharmaceutical Group and Sino Biopharmaceutical respectively recognizing an impairment loss of 0.162 billion yuan and 14.1448 million yuan in assets.
The transfer did not reach a deal; it was intended to sell 5% equity of special treat Jiuzhi to yifeng pharmacy chain two years ago, but now it has "blown up" | Quick read of the announcement.
① The major shareholder of Jiuzhitang Co., Ltd., Li Zhenguo, has terminated the stock transfer agreement with yifeng pharmacy chain; ② A representative of yifeng pharmacy chain stated that their commercial cooperation with Jiuzhitang Co., Ltd. will continue, and the yifeng pharmacy chain's acquisition of Jiuzhitang pharmacy two years ago is unaffected; ③ Currently, yifeng pharmacy chain holds 4.99% of the shares in Jiuzhitang Co., Ltd., making it the third largest shareholder after heilongjiang state-owned assets and Li Zhenguo.
Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.
①At the earnings conference, fosun pharma indicated that due to the continued expansion of innovative drugs and other factors, the company's performance in Q3 improved year-on-year. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the prompt market entry of injectable type A botulinum toxin in china. ③ The privatization process of henlius and the accessibility of CAR-T products have also attracted significant attention.
Jiangsu Sihuan Bioengineering's actual controller has been given a "red card" for lifetime market ban again, and Lu Keping and his son are expected to be fined nearly 30 million yuan. Read the announcement quickly.
①Due to the ST Weichuang suspected of illegal disclosure of information, jiangsu sihuan bioengineering's ultimate controller Lu Keping and the company's director Lu Yu father and son received a "sky-high" fine. ②In this case, Lu Keping has issues such as keeping the identity of the ultimate controller "secret" and has once again been subjected to a lifetime ban from the securities market. ③According to the pre-notification of administrative penalties, Lu Keping and his son were fined a total of nearly 30 million yuan.
The decline in the pharmaceutical sector is affecting overall revenue. Fosun Pharma: Will focus on building super 1 billion yuan big varieties | Earnings conference highlights.
Fosun Pharma's revenue from innovative drugs in the first half of the year exceeded 3.7 billion yuan, accounting for about 18% of the overall revenue. Wu Yifang revealed that the business of innovative drugs will strive to achieve a compound annual growth rate of 30% in the next few years. Wu Yifang said that the privatization of Henlius is currently underway, and the entire business and pipeline of Henlius will be deeply integrated with Fosun Pharma through privatization.